// App-Quantinova.ai

BSH2020‐PO‐009 : Efficacy of FMS‐like Tyrosine Kinase 3 (FLT3) inhibitors in patients with acute myeloid leukemia

Researchers

Presenter

  • T. W. Htut

Principal Investigators

  • S. Ball

  • N. Khandelwal

  • S. Wongsaengsak

  • F. Mogollon-Duffo

  • N. Jahan

  • M. Quirch

  • N. D'cunha

  • K. Z. Thein

Medical Centers

  • Department of Pharmacy, Aberdeen Royal Infirmary, NHS Grampian, Aberdeen

  • Internal Medicine

  • Hematology Oncology, Texas Tech University Health Sciences Center, Lubbock, TX

  • Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • Fms related tyrosine kinase 3

Drug/Treatment

  • gilteritinib

  • Midostaurin

  • quizartinib

  • Sorafenib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Randomized

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved